WASTE MANAGEMENT OR REVERSE DISTRIBUTION OF MEDICINES IN UKRAINE
DOI:
https://doi.org/10.11603/2312-0967.2022.4.13747Keywords:
pharmaceutical industry, medicines, medical devices, reverse distribution, logistics and waste managementAbstract
The aim of the work. The purpose of the study was a comparative analysis of two legislative acts, which will allow to establish the logistics of the reverse distribution of medicines and medical devices, which at the end of their life cycle will acquire the status of waste.
Materials and Methods. The materials were the structure and content of the provisions of two normative legal acts that had the status of "active" – the Law of Ukraine "On Waste" and the one "coming into force" – the Law of Ukraine "On Waste Management". The methods of analysis, grouping and modeling were used.
Results and Discussion. The list of licensees who have permission to conduct economic activities with various types of medical (pharmaceutical) waste has been studied. An analysis of the similarities and differences of two legislative acts – the current one and the one coming into force on waste management in Ukraine – has been carried out. Approaches are proposed and threats are foreseen, which must be taken into account when developing medical (pharmaceutical) sectoral normative legal acts.
Conclusion. A comparative analysis of the two Laws of Ukraine made it possible to establish that the new legislation is more progressive and regulates significantly more economic functions. However, the state and the legislator shift more responsibility to the waste producer and local (regional) self-government bodies. It is predicted that the legislator will introduce stricter liability for improper waste management. It is recommended to take into account the circumstances, namely the Covid-19 pandemic and the war with the Russian Federation, which led to the accumulation of large volumes of used medicines and medical devices that were imported into the territory of Ukraine, when developing sectoral medical (pharmaceutical) normative legal acts.
References
Stych M, Pawlica B. Reverse drug distribution in Poland. Curr. Issues Pharm. Med. Sci., 2021;34(3): 149-153. Available from: https://doi.org/10.2478/cipms-2021-0028 DOI: https://doi.org/10.2478/cipms-2021-0028
Khan F, Ali Y. Implementation of the circular supply chain management in the pharmaceutical industry. Environ. Dev. Sustain., 2022;24(12): 13705-31. Available from: https://doi.org/10.1007/s10668-021-02007-6 DOI: https://doi.org/10.1007/s10668-021-02007-6
Al-Awamleh H, Alhalalmeh M, Alatyat Z, Saraireh S, Akour I, Alneimat S, & Al-Hawary S, et al. The effect of green supply chain on sustainability: Evidence from the pharmaceutical industry. Uncertain Supply Chain Manag., 2022;10(4): 1261-70. Available from: http://dx.doi.org/10.5267/j.uscm.2022.8.002 DOI: https://doi.org/10.5267/j.uscm.2022.8.002
Ranjbar Z, Mirzazadeh A. The forward and reverse pharmaceutical supply chain network design considering tainted product delivery. Int. J. Logist. Syst. Manag., 2019,33(2): 205-20. Available from: https://doi.org/10.1504/IJLSM.2019.100110 DOI: https://doi.org/10.1504/IJLSM.2019.100110
Lima PAB, Delgado FCM, dos Santos TL, Florentino AP. Medications reverse logistics: A systematic literature review and a method for improving the Brazilian case. Cleaner Logist. Supply Chain. 2022; 100024. Available from: https://doi.org/10.1016/j.clscn.2021.100024 DOI: https://doi.org/10.1016/j.clscn.2021.100024
Luna RA, Emerenciano Viana FL. The role of the national solid waste policy in reverse logistics in pharmaceutical companies. RGSA – Revista de Gestão Social e Ambiental, 2019, 13 (1): 40-56. Available from: https://doi.org/10.24857/rgsa.v13i1.1640 DOI: https://doi.org/10.24857/rgsa.v13i1.1640
Ismail LB, Alawamleh M, Aladwan K, Alragheb AA. The relationship between green SCM practices and organisational performance: Evidence from Jordanian pharmaceutical manufacturers. Int J Logist Syst Manag. 2019;34(2): 172-92. Available from: https://doi.org/10.1504/IJLSM.2019.102209 DOI: https://doi.org/10.1504/IJLSM.2019.102209
Lahjouji M, Bassou AA, Alami JE, Hlya M, Lahjouji O. A new mathematic model for humanitarian pharmaceutical supply chain to reduce obsolesence cost. J Theor Appl Inf Technol., 2022;100(9): 3107-3119. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85131747888&partnerID=40&md5=612027cbcbaf6a9d4c56684908716777
Makaleng MS, Lambert KR. Evaluation of Reverse Logistics in Challenges within the Manufacturing Pharmaceutical Companies. Emerg. Sci J 2021;2021:5(4): 486-496. DOI: 10.28991/esj-2021-01291 DOI: https://doi.org/10.28991/esj-2021-01291
Ribeiro DP, de Oliveira UR, da Silva César A, Aprigliano Fernandes V. Evaluation of medicine reverse logistics practices in hospitals. Sustainability. 2021;13(6): 3496. Available from: https://doi.org/10.3390/su13063496 DOI: https://doi.org/10.3390/su13063496
Manzolillo B. Reverse logistics: A solution for medicines disposition at home | [Logística inversa: Una solución a la disposición de medicamentos en el hogar]. Gac Méd Caracas. 2021;129(1): 13-21. DOI: 10.47307/GMC.2021.129.1.3 DOI: https://doi.org/10.47307/GMC.2021.129.1.3
[On waste: Law of Ukraine], adopted on March 5, 1998, revised on October 16, 2020, No. 187/98-VR. Official bulletin of Ukraine. 1998, 13: 23, act code 5121/1998.
[On waste management: Law of Ukraine], adopted on June 20, 2022, enters into force on July 9, 2023b No. 2320-IX. Official bulletin of Ukraine. 2022, 56: 21, Article 3270, act code 112458/2022.
[License register (hazardous waste management)]. URL: https://mepr.gov.ua/content/perelik-licenziativ-na-provadzhennya-gospodarskoi-diyalnosti-z-povodzhennya-z-nebezpechnimi-vidhodami.html
Abahussain, EA, Ball DE. Disposal of unwanted medicines from households in Kuwait. Pharm World Sci. 2007, 29: 368–373. Available from: https://doi.org/10.1007/s11096-006-9082-y DOI: https://doi.org/10.1007/s11096-006-9082-y
SanJuan-Reyes N, Gómez-Oliván LM, Islas-Flores H, Castro-Pastrana LI. Control of environmental pollution caused by pharmaceuticals. In: Ecopharmacovigilance. The Handbook of Environmental Chemistry; Switzerland: Springer, Cham; 2017;66. P. 255–264. Available from: https://doi.org/10.1007/698_2017_152 DOI: https://doi.org/10.1007/698_2017_152
Kohl S. EAHP opinion on pharmaceuticals in the environment. Eur J Hosp Pharm. 2019;26(4): 235-6. Available from: https://ejhp.bmj.com/content/26/4/237 DOI: https://doi.org/10.1136/ejhpharm-2019-002004
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Pharmaceutical Review / Farmacevtičnij časopis
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors who publish their materials in this journal agree with the following terms:
- Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal
. - Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.
Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).
